[144] Corbus Pharmaceuticals Holdings, Inc. SEC Filing

A holder of Corbus Pharmaceuticals Holdings (symbol CRBP) common stock has filed a notice of proposed sale under Rule 144.

Rhea-AI Filing Summary

A holder of Corbus Pharmaceuticals Holdings (symbol CRBP) common stock has filed a notice of proposed sale under Rule 144. The filing covers 20,000 shares of common stock, to be sold through Stifel Nicolaus & Company on the Nasdaq, with an aggregate market value of $812,600. These shares were acquired on February 13, 2026 as restricted stock units granted by the issuer as equity compensation, and became payable on the same date. The notice also confirms the seller states they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 filing for CRBP disclose?

The Form 144 for CRBP reports a proposed sale of 20,000 common shares through Stifel Nicolaus on the Nasdaq, with an aggregate market value of about $812,600. The shares were acquired as restricted stock units on February 13, 2026.

How many CRBP shares are proposed to be sold under this Form 144?

The filing covers a proposed sale of 20,000 CRBP common shares. These shares have an indicated aggregate market value of approximately $812,600, based on the price used in the notice. They represent a small portion of the 95,021,382 shares outstanding cited.

How were the CRBP shares in this Form 144 acquired?

The 20,000 CRBP shares in this notice were acquired on February 13, 2026 via restricted stock units granted by the issuer as equity compensation. The filing lists the issuer itself as the source of the award, rather than an open-market purchase.

Which broker and exchange are involved in the CRBP Form 144 sale?

The proposed sale uses Stifel Nicolaus & Company Inc. as broker and lists the Nasdaq as the securities exchange. The filing indicates that 20,000 common shares of CRBP could be sold through this broker on that market.

What does the Form 144 say about CRBP’s total shares outstanding?

The notice states that 95,021,382 CRBP common shares are outstanding. This figure provides context for the 20,000-share proposed sale, showing that the filing relates to a relatively small portion of the company’s total equity base.

Does the CRBP Form 144 mention any undisclosed negative information?

The person filing the notice represents that they do not know of any undisclosed material adverse information about CRBP’s current or prospective operations. This is a standard representation required when submitting a Rule 144 sale notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:02 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001626003
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Corbus Pharmaceuticals Holdings, Inc.
SEC File Number	001-37348
Address of Issuer	500 RIVER RIDGE DRIVE NORWOOD MASSACHUSETTS 02062
Phone	617-963-0103
Name of Person for Whose Account the Securities are To Be Sold	Cohen Yuval
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	20000	812600.00	95021382	02/13/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/13/2026	Restricted Stock Units	Issuer			20000	02/13/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Yuval Cohen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)